Copenhagen-based hearing aid manufacturer Oticon, part of the Demant Group (CPH: DEMANT) on Wednesday introduced Oticon Zeal, a new in-the-ear hearing aid designed to eliminate the traditional trade-off between discreet design and full functionality, marking the creation of a new hearing aid category, NXT In-the-Ear.
Oticon Zeal integrates the company's BrainHearing technology to deliver clear, natural sound in all environments via the use of second-generation AI sound processing. The device offers same-day fitting, all-day battery life, and seamless connectivity, targeting users who value both aesthetics and advanced performance.
The new model is powered by encapsulation technology, similar to that used in pacemakers, enabling compact construction with durability and high moisture resistance. Its triple-function antenna is designed to ensure strong wireless connectivity while maintaining a deep, secure in-ear fit.
Oticon Zeal supports Google's Fast Pair feature for Android users and incorporates Auracast technology for enhanced audio streaming in public venues. The device also features seamless, stable connectivity with Apple products and can be controlled through the Oticon Companion app.
The rechargeable lithium-ion battery provides up to 20 hours of operation, with quick charging options offering four hours of use from just 15 minutes of charge.
Oticon positions Zeal as a complement to its existing Oticon Intent line, expanding its portfolio to better address diverse hearing needs across global markets.
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system